Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Ambrx Biopharma's Anvatabart opadotin?
Anvatabart opadotin is a monoclonal antibody conjugated commercialized by Ambrx Biopharma, with a leading Phase II program in Human Epidermal...
Anvatabart opadotin by Ambrx Biopharma for Solid Tumor: Likelihood of Approval
Anvatabart opadotin is under clinical development by Ambrx Biopharma and currently in Phase I for Solid Tumor. According to GlobalData,...
Anvatabart opadotin by Ambrx Biopharma for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Anvatabart opadotin is under clinical development by Ambrx Biopharma and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction....
Anvatabart opadotin by Ambrx Biopharma for Metastatic Breast Cancer: Likelihood of Approval
Anvatabart opadotin is under clinical development by Ambrx Biopharma and currently in Phase I for Metastatic Breast Cancer. According to...
Anvatabart opadotin by Ambrx Biopharma for Esophageal Cancer: Likelihood of Approval
Anvatabart opadotin is under clinical development by Ambrx Biopharma and currently in Phase I for Esophageal Cancer. According to GlobalData,...
Anvatabart opadotin by Ambrx Biopharma for Gastric Cancer: Likelihood of Approval
Anvatabart opadotin is under clinical development by Ambrx Biopharma and currently in Phase I for Gastric Cancer. According to GlobalData,...
ARX-517 by Ambrx Biopharma for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
ARX-517 is under clinical development by Ambrx Biopharma and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...
Risk adjusted net present value: What is the current valuation of Ambrx Biopharma's ARX-517?
ARX-517 is a monoclonal antibody conjugated commercialized by Ambrx Biopharma, with a leading Phase I program in Metastatic Castration-Resistant Prostate...